FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE in MAC Lung Disease, PDUFA Set for January 28, 2027
核心洞察
The FDA accepted Insmed's supplemental New Drug Application for ARIKAYCE in Mycobacterium avium complex lung disease (搜索) and granted Priority Review with a PDUFA target action date of January 28, 2027.
The application seeks full approval based on the Phase 3b ENCORE study, which met its primary endpoint and multiplicity-controlled secondary culture conversion endpoints in 425 adults.
Full approval would fulfill the post-marketing requirement tied to ARIKAYCE's 2018 accelerated approval and could extend the label to patients earlier in their disease course.
The U.S. Food and Drug Administration has accepted Insmed Incorporated's Supplemental New Drug Application (sNDA) for ARIKAYCE (amikacin liposome inhalation suspension) for review in Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. The agency granted Priority Review and set a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).
The FDA grants Priority Review to applications for medicines that, if approved, would provide a significant improvement in safety or effectiveness in the treatment of a serious condition.
"The FDA's acceptance of this application marks a pivotal moment in our ambition to change the treatment paradigm for MAC lung disease," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "MAC lung disease is progressive, the longer the infection persists, the greater the damage to lung tissue and the harder it becomes to treat. If full approval is granted, ARIKAYCE could reach patients earlier in their disease course, including those newly diagnosed or facing recurrent infections."
From Accelerated to Full Approval
ARIKAYCE received FDA accelerated approval in 2018 for refractory MAC lung disease and was the first product approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), a pathway enacted under the 21st Century Cures Act to advance development of antibacterial therapies for serious or life-threatening infections in patients with unmet needs.
The current U.S. indication is limited to adults with limited or no alternative treatment options who do not achieve negative sputum cultures after a minimum of six consecutive months of a multidrug background regimen. That accelerated approval was based on achieving sputum culture conversion, defined as three consecutive negative monthly sputum cultures, by Month 6, and clinical benefit has not yet been established. The sNDA under review seeks full approval and would fulfill the post-marketing requirement associated with the accelerated approval.
ENCORE Study Design and Results
The filing is supported by the Phase 3b ENCORE study, the pivotal trial conducted to fulfill that post-marketing requirement. ENCORE was a randomized, double-blind, placebo-controlled study evaluating ARIKAYCE plus multidrug therapy in patients with a new occurrence of MAC lung infection who had not received antibiotics.
The study enrolled 425 patients across 177 sites globally, including patients experiencing their first MAC infection (82.4%) or their second or third infection (17.6%). Patients were randomized 1:1 to receive once-daily ARIKAYCE plus multidrug therapy (azithromycin 250 mg plus ethambutol 15 mg/kg; n=213) or placebo plus multidrug therapy (azithromycin 250 mg plus ethambutol 15 mg/kg; n=212) for 12 months, followed by three months off treatment to assess durability of culture conversion.
The primary endpoint was change from baseline in Respiratory Symptom Score (RSS) at Month 13. The study met its primary endpoint and its multiplicity-controlled secondary culture conversion endpoints, demonstrating statistically significant improvements in respiratory symptoms and culture conversion compared with multidrug therapy alone. Patients treated with ARIKAYCE achieved earlier, greater and more durable culture conversion than those receiving comparator therapy. The safety profile was consistent with the known safety profile of ARIKAYCE, with no new safety signals observed.
Safety Profile
ARIKAYCE carries a boxed warning. Hypersensitivity pneumonitis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared with background regimen alone (0%); most affected patients discontinued ARIKAYCE and received corticosteroids. Hemoptysis occurred in 17.9% versus 12.5%, bronchospasm in 28.7% versus 10.7%, and exacerbations of underlying pulmonary disease in 14.8% versus 9.8%.
Ototoxicity was reported in 17% of patients on ARIKAYCE plus background regimen versus 9.8% on background regimen alone, driven primarily by tinnitus (7.6% versus 0.9%) and dizziness (6.3% versus 2.7%). Nephrotoxicity was observed in trials but not at a higher frequency than background regimen alone. Serious hypersensitivity reactions including anaphylaxis have been reported. ARIKAYCE is contraindicated in patients with known hypersensitivity to any aminoglycoside.
In Trial 1, the most common adverse reactions at an incidence of 5% or greater for ARIKAYCE plus background regimen versus background regimen alone were dysphonia (47% vs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%), musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%), exacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%), headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs 1%), and chest discomfort (5% vs 3%).
Delivery Technology and Disease Burden
ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE liposomal technology delivers amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. The drug is administered once daily using the Lamira Nebulizer System, developed by PARI Pharma GmbH, a quiet, portable device that aerosolizes ARIKAYCE via a vibrating, perforated membrane.
ARIKAYCE is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend its use for appropriate patients.
MAC lung disease is a rare and serious disease that can significantly increase morbidity and mortality. Symptoms often worsen over time and include chronic cough, dyspnea, fatigue, fever, weight loss, and chest pain. In some cases the disease causes severe, even permanent lung damage, and can be fatal. Insmed describes MAC lung disease as an emerging public health concern worldwide with significant unmet need.
Regulatory Next Steps
Beyond the U.S. review, Insmed plans to review the ENCORE data with the Pharmaceuticals and Medical Devices Agency (PMDA) in the fourth quarter of 2026 to support potential label expansion in Japan.